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Abstract:  Domoic acid was identified as the toxin responsible for an outbreak of human 
poisoning that occurred in Canada in 1987 following consumption of contaminated blue 
mussels [Mytilus edulis]. The poisoning was characterized by a constellation of clinical 
symptoms and signs. Among the most prominent features described was memory impairment 
which led to the name Amnesic Shellfish Poisoning [ASP]. Domoic acid is produced by 
certain marine organisms, such as the red alga Chondria armata and planktonic diatom of the 
genus Pseudo-nitzschia. Since 1987, monitoring programs have been successful in preventing 
other human incidents of ASP. However, there are documented cases of domoic acid 
intoxication in wild animals and outbreaks of coastal water contamination in many regions 
world-wide. Hence domoic acid continues to pose a global risk to the health and safety of 
humans and wildlife. Several mechanisms have been implicated as mediators for the effects of 
domoic acid. Of particular importance is the role played by glutamate receptors as mediators 
of excitatory neurotransmission and the demonstration of a wide distribution of these 
receptors outside the central nervous system, prompting the attention to other tissues as 
potential target sites. The aim of this document is to provide a comprehensive review of ASP, 
DOM induced pathology including ultrastructural changes associated to subchronic oral 
exposure, and discussion of key proposed mechanisms of cell/tissue injury involved in DOM 
induced brain pathology and considerations relevant to food safety and human health. 
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1. Introduction 
 
Domoic acid [DOM] was identified as the causative agent of the 1987 human poisoning incident in 
Canada after consumption of contaminated blue mussels [Mytilus edulis] [1-6]. The poisoning was 
characterized by a constellation of clinical symptoms and signs, involving multiple organ systems, 
including the gastro intestinal tract, the central nervous system (CNS) and the cardiovascular system. 
Among the most prominent features described was memory impairment which led to the name 
Amnesic Shellfish Poisoning [ASP] [1,2,4,7,8]. DOM is produced by different species of Pseudo- 
nitzschia [9-13]. and other marine organisms such as the red alga Chondria armata [14DOM can 
potentially enter the food chain by contaminating shellfish and other types of seafood. The most 
common vector is the blue mussel [Mytilus edulis]
 [5-17], but can also be present in other shellfish and 
crustaceans [5,18-20]. Although, depuration occurs with time, harvesting and consumption of the 
shellfish at the time of contamination can lead to human or animal intoxication [21]. 
Specific control measures have been implemented in Canada and around the world to prevent food-
borne illness associated with DOM in bivalves [22-23]. Although these measurements have been 
successful in preventing other episodes of ASP, there are reports of DOM intoxication in wild animals, 
including sea lions, whales, sea otters and sea birds [21,24-28] 
, as well as reports of coastal water contamination in many world regions [12,13,29-32]. Harmful 
algal blooms (HABs) appear to be increasing worldwide, including those of the Pseudo-nitzschia 
species which produce DOM. This is having particular impact on sea lions health off the California 
coast [28]. Two separate clinical syndromes are now described in these animals: one associated with 
acute DOM toxicosis as previously documented, and a second novel neurological syndrome 
characterized by epilepsy described as a consequence of chronic sub-lethal exposure to the toxin [28]. 
Although most of the data available for DOM neurotoxicity is from adults humans and animals there is 
increasing evidences that DOM is highly toxic to the developing brain with specie variations on 
susceptibility and health impact [33-43]. There is also evidence that DOM crosses the placenta and can 
be detected in milk, opening the possibility of a risk for fetal and neonatal exposure [28,40,44,45]. 
Hence DOM is considered a prominent environmental neurotoxin posing a global risk to the health and 
safety of humans and wildlife.  
The toxicology of DOM and the molecular integrative basis for its toxicity have been reviewed in 
recent publications [23,46-49] and by the “Joint FAO/WHO/IOC ad hoc Expert Consultation on 
Biotoxins in Molluscan Bivalves” [23,49]. DOM is a water soluble tricarboxylic acid and its potential 
toxicity is mitigated by its toxicokinetics, as it is poorly absorbed by the gut, poorly penetrates the 
blood brain barrier [BBB] and has a very short half life in most tissues compartments [3,48,50-53]. 
Hence, factors altering these parameters such as poorly developed BBB during brain development, age 
and pre-morbid pathologies [e.g. renal diseases] have been identified as risk factors for DOM toxicity 
[38,41,47,54-58]. 
DOM is structurally similar to another known toxin, kainic acid [KA]. Both are excitatory amino 
acid [EAA] analogues of glutamate, a major excitatory neurotransmitter in the brain that is known to 
activate glutamate receptors [GluRs]. DOM induces excitotoxicity by an integrative action on 
ionotropic GluRs [iGluRs] at both sides of the synapse for which it has high affinity, preferentially the 
KA subtype, coupled with an effect that prevents the channel from rapid desensitization [48,59-79]. A Mar. Drugs 2008, 6                 
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synergistic effect of DOM with endogenous glutamate and NMDA receptors agonists, has been 
demonstrated in vitro and in vivo, which contributes to the excitotoxicity [67,79,80].  
This document includes: 1) a summary of ASP, 2) a review of the pathology associated with DOM 
toxicity including highlights and illustrations of some key neuropathology features, 3) illustration and 
description of the ultra structural changes observed in rat hippocampus associated to subchronic oral 
exposure [81-83], 4) age and gender susceptibility, 5) overview of key mechanisms of cell/tissue injury 
in relation to DOM induced brain pathology, 6) considerations relevant to food safety and human 
health.  
2. Human Data “Amnesic Shellfish Poisoning” (ASP) 
In the 1987 outbreak of DOM intoxication in Canada, the epidemiology data reported over 200 
cases of mussel related illness, of which 107 [47 men and 60 women] fulfilled the definition of ASP 
and an additional 38 were considered as probable cases. Forty nine were between 40 and 59 years old 
and 38 patients were 60 years or older. Amnesic Shellfish Poisoning (ASP) is the syndrome 
encompassing the clinical symptoms and signs described in humans intoxicated with DOM. The 
clinical presentation was characterized by the presence of gastrointestinal symptoms within 24 hours, 
neurological symptoms within 48 hours [2,4,7,84-87]. Symptoms of illness included nausea, vomiting, 
abdominal cramps, diarrhea, headache, unstable blood pressure, cardiac arrhythmias and neurological 
dysfunction, including coma, seizures and memory loss [7,84-87]. 
The 19 most severe cases were hospitalized from 4 to 101 days, 12 of these were admitted to 
intensive care, and 3 died in hospital between 12 and 18 days after admission. Another patient died 
after 3 months. Increased age was identified as a risk factor for both the severity of the illness and 
memory loss. Males were also found to be more susceptible. All severely ill patients less than 65 years 
old had pre-existing illnesses [7,84-87]. 
Fourteen individuals [44 - 87 years old] were followed and assessed using neuropsychological 
testing, assessment of motor function and positron emission tomography [PET] [88]. All patients were 
confused and disoriented 1.5-48 hours post-exposure. Their behaviour ranged from agitation or 
somnolence to coma, with maximum deficits between 4 hr and 72 hr post-exposure. Neurological 
symptoms included various types of seizures, myoclonus, and memory deficit. Most patients improved 
within 24 hours to 12 weeks. Anterograde memory disorder with relative preservation of other 
cognitive functions was described as a prominent feature and was considered a hallmark of DOM 
intoxication. Those individuals with a moderate memory disturbance were generally able to encode 
information, but had delayed recall. More severely affected individuals had some difficulty learning 
verbal and visuospatial material with impairment of delayed recall. The ability to form concepts was 
generally maintained.  
During the acute phase of the illness, all patients were unsteady and showed generalized weakness. 
A few patients showed alternating hemiparesis and ophthalmoplegia. Spastic hemiparesis persisted for 
24-36 hours post exposure. Ophthalmoplegia resolved within 10 days post-exposure. Four and six 
months post-exposure, several patients had distal atrophy, weakness of the extremities and 
hyporeflexia with clinical and electromyography findings consistent with an acute non-progressive 
neuronopathy involving anterior horn cells or diffuse axonopathy predominantly affecting motor 
axons. Mar. Drugs 2008, 6                 
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Autopsy of deceased individuals showed brain damage characterized by neuronal necrosis and 
astrocytosis particularly in the hippocampus and the amygdaloid nucleus [89,90]. Lesions in the 
claustrum, secondary olfactory areas, the septal area and the nucleus accumbens were also observed. 
The thalamus and subfrontal cortex were damaged in some patients and pre-morbid, concomitant 
cerebrovascular disease was evident in the brain of some victims. Neurofibrillary tangles and senile 
plaques, typical features of Alzheimer’s disease, were not observed in these patients [89-90].  
Cendes et al. [91] subsequently reported the clinical and neuropathology findings of an 84-year-old 
man who suffered ASP in1987 died of pneumonia 3.25 years after DOM exposure. The patient 
developed nausea and vomiting 1 hour post-ingestion of the contaminated mussels, and became 
progressively disoriented and somnolent. Thereafter, he became comatose and had complex partial 
status epilepticus, eventually involving the right hemibody. Electroencephalograms showed a diffuse 
slowing of background activity, periodic lateralized epileptiform discharges over the left hemisphere 
and subsequently bitemporal independent epileptic abnormalities. Computed tomographic scans of the 
patient's brain showed mild ventricular enlargement and cerebral atrophy consistent with his age. The 
patient’s seizures were treated with medication and 4.5 months following intoxication, the patient was 
discharged from hospital. Although he was now seizure-free, he had severe impairment of anterograde 
memory. Approximately 1 year post-intoxication, he experienced complex partial seizures consisting 
of staring, twitching of the left lower part of the face and then clonic movements of the left arm and 
leg. It was suggested that temporal lobe epilepsy following DOM exposure might develop after a 
"silent period" of one year. Magnetic resonance images revealed a hyper-intense signal and marked 
atrophy of both hippocampi. A positron emission tomogram showed a bitemporal decrease in glucose 
metabolism and neuropsychological evaluation indicated severe memory impairment for both verbal 
and nonverbal material. At autopsy, gross examination of the patient's brain revealed atrophy of the 
hippocampi and a slight dilatation of the ventricular system and of the sylvian fissure. Histology of the 
hippocampus showed complete neuronal loss in the CA1 and CA3 regions, almost total loss in the 
CA4 and moderate loss in the CA2 region. The amygdala showed patchy neuronal loss in medial and 
basal portions. There was neuronal loss and gliosis in the overlying cortex. Mild to moderate neuronal 
loss and gliosis were seen in the dorsal and ventral septal nuclei, the secondary olfactory areas, and the 
nucleus accumbens. Reactive astrocytes were found in the sixth cortical layer and subjacent white 
matter in the orbital and lateral basal areas, the first and second temporal gyri, the fusiform gyrus, the 
parietal parasagittal cortex, and the insula. No abnormality was seen in the frontal parasagittal, the 
cingulate, the lateral parietal regions, or any part of the occipital cortex [91]. These data provide 
clinical and histopathology evidence of the long term squeals of acute intoxication of DOM in humans, 
serving as a reference for data attained from experimental animals and wildlife. 
3. Toxicologic Pathology of Acute Exposure to Domoic Acid 
3.1 Brain histopathology and anatomical distribution 
Data from human autopsies, from rodent and non-human primate toxicology studies and from sea 
lions that died of DOM intoxication provide a comprehensive description of the acute brain pathology 
associated with DOM toxicity [24,26,46,89,92-104]. Despite the differences in species, data collection, Mar. Drugs 2008, 6                 
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history of events and study design there is an overall agreement regarding the histopathology of the 
brain lesions associated with acute DOM toxicity and its sequels.  
Figure 1. Brain of a control rat after trans-cardiac perfusion with heparinized Tyrode=s 
solution followed by 10% neutral buffered formalin. All images are from paraffin sections 
stained with H&E. A) Cross section of a hippocampus showing the granular cell layer 
(GL) of the dentate gyrus (DG), the molecular layer (ML), the CA3 and the CA4 regions. 
Objective x10. B) Shows the CA3 region with well preserved pyramidal cells (Py). Blood 
vessels are seen as white spaces with the endothelial cells at the periphery (arrow). 
Objective x40. C) Cross section of both hippocampal formations (Hi) showing the dentate 
gyrus (DG), the CA3, CA2 and CA1 regions. This image is a scanned mid coronal section 
of the rat brain. For anatomical reference see technical notes. 
 
 
Acute brain damage (Figures 1-6) is characterized by neurodegenerative changes consisting of 
neuronal shrinkage, vacuolization of the cytoplasm, cell drop out, edema, microvacuolation of the 
neuropil and hydropic cytoplasmic swelling of resident astrocytes. These changes have preferential 
distribution within structures of the limbic system [46,97,99,101-106]. The hippocampus (Figure 1) 
[107], among other brain regions, has been identified as a specific target site having high sensitivity to Mar. Drugs 2008, 6                 
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DOM toxicity, particularly the pyramidal neurons in the CA3, CA4 or hilus of the dentate gyrus [DG] 
[93,96,98-101,103,104,106,108]. The DG and CA1 region are also affected, whereas the CA2 region is 
often spared [96,98,-101,103,104,106]. Although damage of the DG has been described in rodents and 
monkeys, the lesion appears to be more prominent in sea lions than in rodents and non-human primates 
[94]. Variations on specie susceptibility or exposure level may be responsible for the prominent 
involvement of the dentate gyrus in sea lions as compared to experimental animals. 
Figure 2. Brain of a rat after trans-cardiac perfusion with heparinized Tyrode=s solution 
followed by 10% neutral buffered formalin. A) Sections of the hippocampus of a rat 
treated with 4 mg/kg bw/ ip of DOM showing cell drop out and neuronal necrosis, 
particularly within the CA3 regions. H&E. Objective x5. B). Higher magnification of the 
CA3 region showing pyramidal neurons (Py) with vacuolar cytoplasm (V). Few shrunken 
neurons (*) and nuclear pyknosis (arrow) are also seen. H&E. Objective x40.  
 
 
The olfactory bulb, the piriform and entorhinal cortices, the lateral septum, the subiculum, the 
arcuate nucleus, and several amygdaloid nuclei are commonly affected [48,100,101,103,104]. The 
retina (Figure 6) and circumventricular organs, particularly the area postrema, have also been 
described as target sites [101,103,104,109,110]. The circumventricular organs lack BBB. Experiments 
in rodents and non-human primates indicate that the area postrema is a target for DOM toxicity, 
suggesting effects on brain stem regions associated with visceral function [101,103,109,110]. The area 
postrema is located at the base of the IVth ventricle and is implicated in the central control of the 
vomit reflex. Vomiting was a prominent feature both in humans and non-human primates intoxicated 
with DOM [4,7,86,87,103]. These emetic effects were observed after oral and parenteral exposure, 
hence both gastric and central neural control mechanisms appeared to be involved. The area postrema 
histopathology changes observed in monkeys exposed to DOM may explain the induced emetic 
response after parenteral administration. Because rodents cannot vomit, this emetic response is not 
observed, but morphologic changes have been reported in the area postrema [109,110]. Other 
circumventricular organs were affected in mice treated with various doses of DOM by intraperitoneal 
injection [110]. These data suggested the circumventricular organs as a potential site of entry of DOM 
for brain exposure. 
A detailed mapping and 3-D reconstruction of DOM –induced neurodegeneration in the mouse 
brain showed that the affected areas included the olfactory bulb, septal areas and the limbic system 
[93]. The lesion distribution described in this study is consistent with earlier reports by other Mar. Drugs 2008, 6                 
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investigators. The anatomical extent of brain lesions induced by DOM has also been identified by 
magnetic resonance imaging microscopy [MRM] in both human [90] and rat [111,112] with similar 
distribution as that described by histopathology.  
Figure 3. Brain of a rat after trans-cardiac perfusion with heparinized Tyrode=s solution 
followed by 10% neutral buffered formalin. A) Hippocampus of a control rat. CA3 regions. 
Chen/Bodian Objective x20. B) Sections of the hippocampus of a rat treated with 4mg/kg 
bw/ip of DOM, showing-marked drop out of pyramidal neurons in the CA3 region. 
Chen/Bodian, Objective x20.  
 
 
Available literature indicates that brain lesions induced by DOM are dose-dependent, acute 
responses more evident in animals treated by intra-peritoneal [i.p] or intravenous [i.v] injections than 
in those exposed by oral administration and they differ in species susceptibility [47]. Recent reports 
support the view that there is a specie specific susceptibility to DOM toxicity [113]. Leopard sharks 
possess the molecular target for DOM but are resistant to doses of DOM known to be toxic to other 
vertebrates, suggesting an intrinsic protective mechanism [114]. 
In the brain, during
 DOM
 excitotoxic insults, neurons undergo rapid swelling in both
 the soma and 
dendrites [99,102,104,115,116]. Dendrites appear as preferential early targets sites for DOM 
excitotoxicity as demonstrated by in vitro studies on hippocampal slices [117]. High susceptibility of 
the dendrites has also been described for glutamate and other EAAs [118].  
Glial cells are also known targets for DOM effects. Acute injury of astrocytes characterized by 
vacuolation and necrosis was observed in toxicology studies using rodents and non-human primates 
[46,102-104,116,119]. Reactive astrocytosis has been described in experimental animals surviving the 
acute effect of DOM. This has also been described in humans that died from ASP and in sea lions 
dying from DOM intoxication [46,91,94,95,98]. These findings are more evident when GFAP 
immunohistochemistry is used as a biomarker (Figure 5).  Mar. Drugs 2008, 6                 
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Figure 4. Brain of monkeys (M. fascicularis) after trans-cardiac perfusion with 
heparinized Tyrode=s solution followed by 10% neutral buffered formalin. A) Section of 
the CA3 region of the hippocampus of a control animal showing well preserved pyramidal 
cells (Py). Blood vessels are seen as white spaces with the endothelial cells at the 
periphery (arrow), H&E Objective x40. B) Sections of the hippocampus of an animal 
treated with 4 mg/kg bw/ ip of DOM showing cell drop out and neuronal necrosis. Most 
pyramidal neurons appear with vacuolar cytoplasm (V). Some nuclear pyknosis (arrow 
head) is also seen. H&E, Objective x40. 
 
 
 
Figure 5. Brain of monkeys (M. fascicularis) after trans-cardiac perfusion with 
heparinized Tyrode=s solution followed by 10% neutral buffered formalin. Histological 
sections were processed for GFAP immunohistochemistry. A) Hippocampus of a control 
animal showing the granular cell layer (GL) of the dentate gyrus and the CA4 region 
showing spaced astrocytes labeled by the GFAP-IH. Some immunolabeled astrocytes are 
clearly identified around blood vessels (arrow), Objective x10. B) Hippocampus of an 
animal treated with a single IV dose (0.055 mg/kg/bw) of DOM. Animal recovered after 
the initial symptoms of toxicity which lasted 90 minutes and included vomiting, gagging, 
lethargy and disorientation. Necropsy was conducted six month after the injection. 
Sections show marked astrocytosis as revealed by the intensity of the GFAP-IH seen in the 
CA4 and subgranular zone (arrow); granular cell layer (GL). Objective x20 
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As supporting evidence of long term sequels of acute intoxication, some studies have evaluated the 
brain pathology induced by single dose of DOM several days after its administration to experimental 
animals [98,120,121]. Ananth et al. [120] report neuronal damage at 1-21 days following the 
administration of DOM with the most severe damage reported after 5 days. Appel [121] conducted 
neuropathology assessment in adult rats seven days after the administration of DOM [2.25 mg/kg i.p.] 
and reported neuronal injury, astrocytosis evidenced by GFAP-immunostain and activation of 
microglia revealed by GSI-B4 histochemistry. The possibility that DOM may activate microglia has 
been suggested by several investigators [46,120]. Mayer’s laboratory has further investigated the role 
of microglia in DOM toxicity using an in vitro model of neonatal rat microglia [122-124]. Their 
observations do not support the hypothesis that a short term [4 to 24 hrs] in vitro exposure to DOM, at 
a concentration toxic to neonatal neurons, activates neonatal rat microglia and the concomitant release 
of pro-inflammatory mediator factors [124]. 
 
3.2 Other tissues as targets for DOM toxicity 
Acute retina injury in adult animals 
Acute studies on rodents and non-human primates showed evidence of retinal injury associated with 
acute DOM and KA toxicity [100-102,116]. The inner nuclear layer is most often affected, but other 
layers can also be involved (Figure 6). The characteristics of the cellular lesion are similar to those 
observed in the hippocampus and are consistent with excitotoxicity. A variety of GluRs and GABA 
receptor subtypes are found in the retina, providing the molecular target for excitatory 
neurotransmissions and excitotoxicity [125,126] and for the induction of the retinal injury seen with 
DOM [127].  
Although eyes were not examined in all animals, retinal lesions were noted in sea lions that died of 
DOM intoxication [94]. The predominant lesion consisted of
 vacuolation of the ganglion cell layer in 
contrast to those described
 in the rat and macaque in which the inner nuclear area
 and outer plexiform 
layer were more affected [94,102-104]. 
Motor sensory abnormalities  
Clinical observations consistent with anterior horn cell and dorsal root ganglion pathology or with a 
diffuse axionopathy in humans [90] have been supported by experimental data [74,128]. Spinal cord 
lesions characterized by focal hemorrhage, neuronal swelling and neuronal vacuolization were found 
in 73% of the animals clinically presenting paralysis/tremor in their extremities 1 to 2 hours after 
DOM injection. These lesions were seen at all spinal cord levels. Neuronal degeneration was mainly 
found in the ventral and intermediate gray matter, whereas cells in the dorsal portion of the spinal cord 
were relatively spared [128]. Dorsal root ganglia cells [DRG] were depolarized by KA and DOM [74] 
supporting the view that ganglia cell are targets for DOM toxicity [129].  
 Mar. Drugs 2008, 6                 
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Figure 6. Retina of a monkey (M. fascicularis) fixed by intraocular injection of 10% 
neutral buffered formalin. Photographs show cross sections of the retina stained with H&E. 
Picture shows the retina of an animal treated with DOM (4mg/kg/bw ip). Cell loss and 
necrosis are present in the INL, GCL and to a lesser extent in the ONL. Vacuoles are easily 
identified in the Ph cell layer, particularly the cones (*) and in the OPL. Cones and rods in 
the Ph layer are identified (arrows). There is also marked loss of cell bodies in the GCL. 
From external to internal: the photoreceptor cell layer (Ph); the outer nuclear layer (ONL); 
the outer plexiform layer (OPL); inner nuclear layer (INL); inner plexiform layer (IPL); 
ganglion cell layer (GCL). Objective x40. 
 
Heart and other target sites 
Cardiovascular clinical manifestations such as unstable blood pressure and cardiac arrhythmias 
observed in humans with ASP were suggestive of a cardiotoxicity induced by DOM [4,86,87,90]. 
Although these symptoms could be associated with effects on the CNS cardiovascular control centers, 
there is evidence supporting the view of a more direct cardiac effect [130]. These include that the 
molecular targets for glutaminergic neurotransmission are ubiquitously expressed in heart and other 
tissues [129,131-133]. Differential distribution of various subtypes of GluRs including AMPA/KA, 
NMDA and mGluRs have been demonstrated in rat, monkeys, and human hearts [139,131-
133,134,135]. In humans AMPA [GluR 2/3]/KA [GluR 5/6/7] and NMDA [R1] subtypes of iGluRs 
showed differential distribution in the working myocardium, wall of blood vessels, intramural ganglia, 
and specific components of the conducting system, providing evidence that the molecular targets for 
excitatory neurotransmission and neurotoxicity of EAAs are present in the human heart. The specific 
distribution of these receptors varied with the receptor subtype and in contrast to non-human primates, 
they were also expressed in the working myocardium and the walls of blood vessels. The function of 
GluRs in heart and other peripheral tissues is starting to be unwrapped. Cumulating evidence suggests 
mediation of functional and pharmacological effects with similar roles of GluRs in the CNS and other 
tissues [129,132,133,136,137]. Recent in vitro studies provide evidence suggesting that stimulation of 
NMDA receptors in the cardiomyocyte may lead to apoptosis via a Ca
+2, ROS, and caspase-3 mediated 
pathway. These findings support the view that NMDA receptors in the heart may play an important 
role in myocardial pathogenesis [138]. Mar. Drugs 2008, 6                 
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The opinion that DOM is cardiotoxic is supported by the observation that the heart was one of the 
most affected organs in sea lions that died of DOM intoxication [24]. Lesions were mostly seen in the 
myocardium and were more frequent in animals that died within 48 hours of stranding. Furthermore, 
DOM was identified as a risk factor associated with myocarditis and dilated cardiomyopathy in 
southern sea otters [139]. 
Evidence suggests that other tissue and organ systems may also be affected by DOM. Mussel 
extract and DOM produced gastric [antral] ulcers, duodenal ulcers, bleeding and ascites [140]. Gastric 
bleeding was observed particularly in animals receiving higher doses. Furthermore, the demonstration 
of GluRs in the ganglia and other structures of the GI tract provide evidence for the molecular target 
for DOM toxicity in these tissues [132] . 
Serum thyroid hormones [T4 and T3] and TSH are altered by several EAAs including KA and 
DOM, suggesting that these compounds can modulate the regulation of hormone secretion from the 
pituitary-thyroid axis [141,142]. The concept of neuroendocrine perturbation by EEAs has been 
pointed out in the past [143-144] and deserves further considerations in light of new evidence that 
DOM crosses the placenta and can be detected in milk, opening the both the possibility of a risk of 
fetal and neonatal exposure [28,40,44,45], and of endocrine disruption effect, which could manifest 
later in life. 
4. Toxicological Pathology of Repeated Exposure to Domoic Acid 
There are numerous reports in the literature on the acute effects of DOM at doses inducing clinical 
symptoms, but less is known about the long term effects of repeated exposure at doses below those 
inducing overt clinical symptoms [81,145-147]. Furthermore, most studies have used intra-peritoneal, 
intravenous or subcutaneous routes of administration. Only two studies are available in the literature 
using the oral route to investigate the toxic effects of repeated doses of DOM, one in monkeys and the 
other in rats [81,147]. DOM was orally administered to 3 cynomolgus monkeys at doses of 0.5 mg/kg 
for 15 days and then at 0.75 mg/kg for another 15 days. No toxic effects were observed in any of the 
parameters evaluated including histopathology of brain and retina using light microscopy [147]. 
Similarly, sub chronic (64 days) oral administration (gavage) of DOM (0, 0.1 or 5 mg/kg/day) to adult 
rats did not induce clinical or histopathology changes as assessed by light microscopy [81]. However, 
electron microscopy [82,83] revealed morphologic changes in the hippocampus of animals treated with 
the high dose (5mg/kg/day). This dose was equivalent to the estimated maximum dose of human 
exposure during the ASP incident and was approximately seven times (5mg/kg) less than that required 
to cause overt clinical signs in the rat [6,81]. Despite this dose being insufficient to produce seizure or 
any clinical signs of neurotoxicity, it did induce morphologic changes, predominately in the CA3 
region of the hippocampus, including: cytoplasmic vacuolization of neurons and astrocytes, as well as 
injury to the mitochondria in the pyramidal cells. The abnormalities in one of the four animals in the 
high dose group were more severe than those observed in the other three. No changes were observed in 
the low dose (0.1 mg/kg/day) group. The 0.1 mg/kg dose was approximately equivalent to that 
resulting from a 50 kg person consuming one 250 grams portion of mussel meat containing the current 
maximum residual limit [MRL] of 20 μg/g. The lack of observed effects at this dose supports the MRL 
of 20 μg/g DOM/gr shellfish meat [23]. However, further investigations are required to assess long 
term effects of oral exposure to low doses of DOM for risk assessment of chronic exposure at doses Mar. Drugs 2008, 6                 
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below the current MRL [23], particularly gestational and post-natal exposure, as there is evidence of 
higher susceptibility of the developing brain to DOM toxicity.  
Figure 7. Brain of rats after trans-cardiac perfusion with heparinized Tyrode=s solution 
followed by a fixative containing 2% glutaraldehyde and 2% paraformaldehyde in 
Tyrode=s solution. Samples selected from the CA3 region were processed for electron 
microscopy (EM). A) CA3 region of the hippocampus of a control rat showing a cluster of 
pyramidal cells with good preservation and integrity of cell membranes and organelles. 
The nucleus (N) and nucleolus (ncl) are easily identified. A well preserved electro dense 
dendritic spine is depicted (arrow). Scale Bar = x2.5μm;  B) CA3 region of the 
hippocampus of a rat treated by gavage with 5.0 mg/kg/day of DOM for 64 days [81]. 
Image shows a pyramidal cell with easily identifiable nucleus (N), the cytoplasm and 
surrounding neuropil with numerous vacuoles (V) of various sizes giving a >Swiss cheese’ 
effect. The neuropil refers to intricate interwoven cell processes including: glial processes, 
synaptic terminals, axons, and dendrites that are interspersed among the nerve cells in the 
gray matter of the CNS. Scale Bar = x2.5μm; C) CA3 region of the hippocampus of a 
control rat showing good preservation and integrity of the neuropil. Mitochondria (M), 
synaptic spines (arrow) and dendrites (D) are identified. Scale Bar = x1.1μm; D) CA3 
region of the hippocampus of a rat treated by gavage with 5.0 mg/kg/day of DOM for 64 
days. Vacuoles (V) and the ‘Swiss cheese’ effect are more apparent at this magnification. 
Some remaining dendritic spines (arrow) can still be identified. There is increased electron 
density of the mitochondria (M) with loss organization of the cristae. Scale Bar = x1.1μm; 
E) High magnification of the CA3 region of the hippocampus of a control rat showing 
good preservation and structural integrity. An electro dense dendritic spine (arrow), 
terminal axon (At), dendrite and mitochondria (M) are identified. Scale Bar = x 0.6μm; F). 
High magnification of the CA3 region of the hippocampus of a rat treated by gavage with 
5.0 mg/kg/day of DOM for 64 days showing loss of structural integrity and marked 
vacuolar (V) dilatation of dendrites. Scale Bar = x 0.6μm 
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Figure 7. Cont. 
 
 
 
Figure 7 illustrates [82,83] the electron microscopy findings observed in the CA3 region of the 
hippocampus of the rats in the high dose group [DOM 5 mg/kg/day]. Here, well preserved neurons and 
astrocytes are seen intermingled with injured cells. Dilatation of the dendrites, vacuoles in the 
cytoplasm and neuropil, and degenerative changes of the organelles, particularly the mitochondria 
were the main features observed in the CA3 region of the hippocampus as compared to controls 
(Figure 7). Dilated processes which were post synaptic to axon terminals and showed dendritic spines 
were identified as dendrite while others which lacked synaptic contact were presumed to be astrocytes 
(Figure 7 C to F). Features, including cell swelling, dilatation of dendrites and vacuoles in the 
cytoplasm, although less severe, were comparable to those previously described in response to acute 
single exposures [99,104,106,116]. The reason for these similarities after acute and sub chronic 
exposure is not known.  
Scattered throughout pyramidal neurons in the CA3 region were mitochondria with an increased 
density of the matrix and disarranged cristae. Electron microscopy  studies using murine cortical 
culture demonstrated that rapid EEAs injury leads to swelling of mitochondria typical of excitotoxic 
cell necrosis, but prolonged exposure to low concentrations of EEAs (AMPA or KA) leads to less Mar. Drugs 2008, 6                 
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typical changes with relative spearing of the mitochondria until late in the injury [148]. Hence, the 
mitochondrial changes in our study (Figure7D) suggest delayed injury and support the view of 
mitochondrial dysfunction in response to excitotoxicity [149].  Recent studies using neuronal cell 
culture provide evidence that the very early neuronal response to excitotoxicity (mitochondrial 
dysfunction and dendritic beading) are linked, and recovery of dendrites is dependent on the degree of 
mitochondrial dysfunction [150]. It is then feasible that this interplay between mitochondrial function, 
spine remodeling and dedritic beading persists after repeated excitotoxic insults. Hence, further 
investigations on long term oral DOM exposure time line and recovery are needed to elucidate the 
sequence of events, the possible point of return whereby cells may be able to recover. 
Microvacuolation and degenerative changes were also observed in the astocytes [82,83,151] and these 
changes are discussed in other publications [151]. 
There are many limitations in the assessment of long term effects of DOM. These include limited 
experimental data on repeated oral exposure to low doses of DOM, a wide species difference in 
susceptibility to DOM toxicity [21,28,94,114,152], age and sex differences in susceptibility, and 
differences in comparative development of the central nervous system among species. Nonetheless, 
data arising from sea lions dying of DOM intoxication provides an excellent account of the long term 
effects of DOM [28,94]. Neuropathology of sea lions dying of DOM intoxication reports gross 
hippocampal atrophy with relative enlargement of the
 inferior horn of the lateral ventricle presented in 
three animals dying 1 month, 5 months, and 10 months after
 stranding. Hippocampal and amygdala
 
lesions were noted in four individuals dying between 9 and 98
 days after intoxication. Positron 
emission tomography demonstrated
 decreased glucose metabolism in the mesial temporal lobes of
 
surviving individuals. Neuronal dropout
 with hippocampal atrophy and marked gliosis were present
 in 
many of the animals. Prominent
 neocapillarization is described in affected neuropil. More recent 
reports provide additional evidence of the long term harmful effects of DOM exposure of sea lions in 
their natural habitat [28]. Clinical signs associated to chronic sub lethal exposure included seizures, 
marked lethargy, inappetence, vomiting, muscular twitching, central blindness blepharospasm and 
abnormal behaviour. Histological examination of the chronic neurological cases that died showed 
chronic lesions in the hippocampus and parahippocampal gyrus, manifested as atrophy of the 
parenchyma due to severe neuronal loss, marked astrocytosis and oligodendrogliosis. The regions 
more often and more severely affected were the dentate gyrus and the CA3 region of the hippocampus, 
but other regions were also affected. The consistent involvement of the dentate gyrus has previously 
been described [94] as a prominent feature in these animals [28,94] as compared to experimental 
animals. These chronic neuropathology lesions were interpreted as likely due to a combination of 
DOM exposure and the effect of ongoing seizure activity. A key observation is that these chronic 
effects were more often see in juvenile animals of both sexes as compared to adult females animals 
that often present with acute toxicosis, supporting the view of higher susceptibility of the developing 
brain to DOM exposure.  
5. Age and gender susceptibility to DOM exposure  
During the ASP incident of 1987, epileptogenic effects and lasting neurological deficits were seen 
primarily in older patients, suggesting a heightened susceptibility to DOM toxicity in the elderly. 
Males also appeared to be more susceptible. It was not clear whether heightened vulnerability arose Mar. Drugs 2008, 6                 
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from an age-related alteration in neuronal response to the toxin, from alterations in the 
pharmacokinetics of the toxin [e.g. impaired clearance due to age or pre-existing disease] or from a 
combination of these factors. Alterations in the pharmacokinetics of DOM, as a function of age, have 
not been systematically investigated to date. However, it is known that DOM is very hydrophilic and 
consequently exhibits relatively poor blood-brain barrier permeability [51]. It has also been established 
that DOM is cleared almost exclusively by the kidney [57]. Both blood-brain barrier integrity and 
renal function are known to be impaired in very young and very old animals relative to normal adults. 
This view is supported by in vitro studies demonstrating an age dependent susceptibility to DOM and 
KA excitoxicity, demonstrating also induced tolerance in the young, but not in the old animals 
[153,154].  
Gender differences and increased susceptibility to DOM toxicity of the developing brain has been 
demonstrated using rodent model, and exposure during pre-natal and early post-natal development 
[37,38,40-42,55,61,155]. Sub-convulsive behavioral abnormal responses were observed in neonatal 
rats administered daily subcutaneous injections of low doses of DOM [5 and 20 μg/kg], or 
pharmacologically equivalent doses of KA [25 and 100 μg/kg] from PND 8-14 [155]. Furthermore, 
daily perinatal administration of low sub-convulsive doses of DOM [0.020 mg/kg DOM s.c.] induced a 
“seizure-like” syndrome in adulthood, manifested when animals were exposed to novel environments 
[41]. These rats displayed permanent changes in hippocampal morphology including altered synaptic 
connectivity and cell loss. More recently the same group demonstrated that a low dose of DOM 
administered parenterally to neonatal rats produced cytoarchitectural changes indicative of abnormal 
development and/or synaptic plasticity. These changes are progressive with age and show regional 
variation within the hippocampal formation. The morphological changes assessed at 90 days after 
treatment consisted of mossy fibers sprouting and associated changes in the trkB receptor population 
in young adults with regional variation throughout the septo-temporal axis of the hippocampus [37]. 
These findings raise concern regarding possible increase in the risk of log term effects if DOM 
exposure occurs during pregnancy and lactation, particularly since it has been demonstrated that DOM 
crosses the placenta and can be detected in milk [28,40,44,45]. However, supporting evidence for 
developmental neurotoxicity of DOM comes from studies conducted either in vitro or in animals 
exposed by parenteral routes, or from findings described in sea lions continually exposed to high doses 
of DOM. Hence, it remains to be elucidated that the effects of chronic exposure to DOM during 
gestation or through lactation at doses below or equivalent to the maximal residual limit of 20 μg/g, 
would not induce clinical or morphologic changes in adult rats [31] (section 3). 
6. Key mechanisms of cell/tissue injury in relation to domoic acid induced brain pathology 
Current evidence on DOM induced neurotoxicity supports the view that the main cause of 
neurotoxicity is the activation of GluRs and the release of endogenous glutamate leading to a cascade 
of events mediating cell and tissue injury (Figure 8). The mechanistic profile proposed for DOM 
tissues/cell injury is known to share similarities with that of brain ischemia, brain trauma and other 
excitotoxins, suggesting a common pathway for tissue injury and response in the CNS and in 
peripheral tissues [129,132,156-158]. Today we witness great advances in our understanding of 
glutamate neurotransmission, mechanisms involved in excitotoxicity, and their role on the pathology 
and treatment of a variety of diseases, including multiple sclerosis, stroke, chronic degenerative Mar. Drugs 2008, 6                 
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neurologic disease and epilepsy [157,159-172]. However it is beyond the scope of this publication to 
review the vast collection of scientific literature currently available on these subjects. Here we provide 
an overview of those aspects more directly relevant to DOM induced pathology (Figure 8).  
6.1 Glutamate receptors [GluRs]  
Glutamate is a major excitatory neurotransmitter in the brain, acting through the glutamate receptor 
[GluRs] family. Olney [173], was the first to recognize that the ubiquitous neurotransmitter glutamate, 
when present in excess, has the potential for excitotoxicity. Subsequently several investigators have 
brought attention to the potential health risks of excitatory compounds when present in food 
[129,132,173-180]. DOM is one of the most potent excitatory compounds that could be found in food 
and is of concern for food safety. DOM is similar in structure and function to kainic acid [KA], which 
is found in the red macroalga Digenea simplex. Both DOM and KA are structurally similar to 
glutamate which allows them to bind to the same receptors and induce neuroexcitatory and neurotoxic 
effects [63,76,155,173,181-183].  
Two classes of GluRs have been characterized in the CNS: ionotropic [iGluRs] and metabotropic 
[mGluRs]. Their cloning has revealed the molecular diversity of the gene families encoding various 
receptor types which are responsible for the pharmacological and functional heterogeneity in the 
brain
184-190. The iGluR family is classified into three major subtypes according to their sequence 
similarities, their electro-physiological properties and their affinity to selective agonists: N-methyl-D-
aspartate [NMDA], alpha-amino-3-hydroxy-5-methyl-4-isoxazole propionic acid [AMPA] and KA 
receptors, each with several encoding gene families. The AMPA family is composed of GluR 1-4; the 
KA family includes GluR 5-7 and Ka 1-2; NMDA includes NMDAR 1 and NMDAR 2A-D [186,189].  
Postsynaptic AMPA receptors are believed to mediate rapid glutaminergic neurotransmission with 
low Ca
2+ permeability. AMPA receptors are invariably co-localised with NMDA receptors indicating a 
close functional relationship between the two ligand-gated cation channel-bearing receptors. AMPA 
activation causes cellular depolarisation and NMDA channel opening with Ca
2+ influx. KA receptors 
are closely related to AMPA receptors and are involved in both pre- and post-synaptic 
neurotransmission [189,191]. Glutamate receptors are targeted and anchored at excitatory synapses 
through a network of scaffolding proteins. These proteins are concentrated at the tip of the post-
synaptic dendritic spine in a region termed the post-synaptic density [PSD]. The PSD is estimated to 
contain more than 200 synaptic proteins that have a myriad of functions [192].  
Much evidence supports the view that DOM and KA are excitotoxic and their toxic effect is 
mediated through the activation of iGluRs with the participation and co-activation of AMPA/KA and 
NMDA receptor subtypes [46,48,61,63,67,79,80,181,193-197]. These receptors are ligand-gated ion 
channels that are activated by glutamate and its agonists, mediating a fast excitatory synaptic 
transmission. Evidence indicates that DOM binds to KA subtypes of iGluRs with high affinity, but is a 
partial agonist [48]. In addition to this high affinity for these receptors, DOM efficacy is the result of 
non-desensitization of the channel [48]. The current view is that DOM excitotoxicity is reached from 
an integrative action at both sides of the synapse leading to depolarization and release of glutamate 
into the synapse. Activation of KA receptors leads to the release of glutamate and in turn activation of 
NMDA receptors. Persistent activation of KA receptors results in elevated levels of intracellular 
calcium [Ca
+2] through the co-operative interactions with NMDA and non-NMDA glutamate subtypes Mar. Drugs 2008, 6                 
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and voltage-dependent Ca
+2 channels [187,189,194,198]. The high concentration of iGluRs in the 
hippocampus and other brain regions provides the substrate for the selective cellular and structural 
excitotoxicity damage observed with DOM toxicity, leading to seizure and cognitive dysfunction. The 
demonstration that GluRs are targeted and anchored at excitatory synapses through a network of 
scaffolding proteins concentrated at the tip of the post-synaptic dendritic spine region [192], and that 
the dendrite has been identified as a preferential target for DOM toxicity opens the possibility that 
these proteins may also be involved in DOM cell injury.  
Toxicologic pathology versus proposed mechanisms of cell/tissue injury. 
The histopathology of acute DOM toxicity viewed in Figures 2-5 resemble those reported with KA 
and are considered characteristic of excitotoxicity [83,104,106,173,175,179,199-203]. Excitotoxicity 
refers to the ability of glutamate and related EAAs to mediate the death of central neurons under 
certain conditions such as intense exposure[79,80,173,204-205]. The GluRs are known to act as 
mediators of inflammation and cellular injury through a common injury pathway. Cell injury 
associated to excitotoxicity can be separated into several overlapping components [46,157,206,207] 
and can be modified by many factors.  
1) The first component is associated to tissue swelling. The iGluRs are ion-gated channels selective 
to Na
+, K
+ and Ca
+2 and any sustained stimulation of the iGluRs may results in osmotic tissue 
damage. Hence, neuronal cell swelling reflects the influx of extra cellular Na
+, Cl
- , water and cell 
volume expansion. These changes are best observed in vitro, as the open architecture of cell culture 
may permit exaggeration of cell volume expansion 
206. Although associated with abnormalities in 
membrane permeability the cells may be able to recover at this stage. Focal swellings along the 
dendrites
 called varicosities are early structural changes and are viewed as a hallmark of excitotoxic 
neuronal injury. The formation
 and resolution of excitotoxic varicosities has been linked to changes 
in the neuronal anion flux. 
2) A second component is associated with increased intracellular Ca
+2 concentration [187,194,206-
209].This component is marked by delayed cell degeneration and complex inter-playing 
mechanisms. A key triggering factor is that glutamate and/or EEAs analogs open  the  voltage-
dependent Ca
+2 channels  through activation and co-operative interactions of NMDA and non-
NMDA GluRs subtypes leading to excessive Ca
+2 influx [157,187,194,206-209]. This excess of 
Ca
+2 is highly toxic for the cells and triggers the activation of several enzyme pathways and 
signalling cascades including: damage of oxidative phosphorylation lowering function and energy 
production by the mitochondria, the activation of phospholipases, protein kinase C, proteases, 
protein phosphatases, nitric acid synthases and the generation of free radicals [120,193,194,210-
213]. The brain is particularly sensitive to the action of free radicals because it lacks normal 
scavengers and contains a large quantity of iron, an important coenzyme in this reaction. The free 
radicals act in the membrane phospholipid, breaking the membranes and destroying the cell. 
 
Activation of phospholipases contributes to the destruction of neuronal membranes and brain 
vascular endothelium, through enzymatic lipid peroxidation and activation of the arachidonic cascade 
with a final production of prostaglandins (thromboxane A2 and prostacyclin) and leucotriens. Upon the Mar. Drugs 2008, 6                 
 
 
197
activation of phospholipase A2, arachidonic acid with its metabolites and platelet-activating factors are 
generated. Platelet-activating factors increase the neuronal Ca
+2 levels by stimulating the release of 
Glu. Arachidonic acid potentiates NMDA- evoked currents and inhibits the re-absorption of Glu into 
astrocytes and neurons. This is exacerbated by a positive feedback mechanism whereby free radicals 
are formed during arachidonic acid metabolism leading to further phospholipase A2 activation. This 
results in an increased concentration of extracellular glutamate which contributes to a sustained 
activation of the GluRs [157,187,206,207,214]. Cysteine transport is also inhibited causing a decrease 
of intracellular reducing sulphydryls and the generation of oxygen radicals leading to cell death. 
Excess Ca2+ stimulates nitric oxide synthase (NOS) and consequently increases the nitric oxide 
(NO) concentration. Over/production of NO from excessive or inappropriate stimulation of NOS 
seems to mediate a major component of excitotoxicity damage. Increased concentration of Ca
+2 raises 
NO via the calmodulin activation of nitric oxide synthetases which generates oxygen radicals. 
Activation of proteases leads to the production of free radicals [138,157,187,206,207,214].  
The excess of intracellular Ca
+2 also induces the activation protein kinase C (PKC) and its 
translocation from the cytoplasm to the membrane. This leads to the phosphorylation of the membrane 
proteins via PKC promoting destabilization of Ca
+2 homeostasis, mediates the extrusion of Ca2+ and 
an increase of the post synaptic sensibility to glutamate [138,157,187,206,207,214].  
Evidence indicates that the mitochondrion plays a central role in the processes of excitotoxic 
neuronal cell degeneration with a web of interactions between Ca
2+ homeostasis, and ATP production, 
the generation and detoxification of reactive oxygen species [215-218]. It is now believed that 
disturbed Ca
+2 and Na
+ ionic homeostasis are key in excitotoxic cell death. The actual death blow 
initiated by irreversible failure of cytoplasmic Ca
+2  homeostasis is referred as delayed Ca
+2 
deregulation. The morphological counterpart of this death cell blow is portrayed in Figure 3 as cell 
drop out. The structural mitochondrial changes observed by electron microscopy (Figure 4) support the 
view of mitochondrial dysfunction in response to DOM toxicity.  
In addition to enzymes of the cell cytosol, the nuclear enzymes are also activated by increase of 
Ca
+2. For example, Ca
+2 may activate endonucleases that result in condensation of nuclear chromatin 
and eventually DNA fragmentation and nuclear breakdown, a process known as apoptosis. Free 
radicals also contribute to DNA fragmentation. DOM can induce some changes consistent with cell 
apoptosis [120,219,220]. There is an overall agreement that the neuronal degeneration associated with 
DOM toxicity is mostly necrotic and is dose dependent [46,83,92,94,97,98,100-
104,106,108,116,219]. Recent studies [219] demonstrate that exposure of mouse cerebellar granular 
neurons [CGNs] to DOM induced cell death, either by apoptosis or by necrosis, depends on its 
concentration. Necrotic damage predominated in response to DOM above 0.1 μM. In contrast, cell 
death by apoptosis was evident after exposure to lower concentrations of DOM [≤0.1  μM]. The 
AMPA/KA receptor antagonist NBQX, but not the NMDA receptor antagonist MK-801, prevented 
DOM-induced apoptosis. Oxidative stress is involved in the apoptotic neuronal cell death associated 
with low concentration DOM exposure. 
3) Other messenger pathways appear to be involved in excitoxicity induced cell and tissue injury 
[221]. GluRs are found localized at the synapse within electron dense structures known as 
postsynaptic density (PSD]. Localization at the PSD is mediated by binding of GluRs to 
submembrane proteins such as actin and PDZ containing protein. PDZ-containing proteins mediate Mar. Drugs 2008, 6                 
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the clustering of receptors and signaling molecules and thereby regulate agonist-induced signal 
transduction in polarized cells such as neurons. These proteins mediate protein-protein interactions 
[192,221]. GluRs (PDZ-containing proteins) bind with numerous signal molecules including nitric 
oxide synthase, providing a mechanism for clustering GluRs with the corresponding signaling 
transduction protein. GluRs associated proteins and excitotoxic signaling result in a free radical 
cascade and activation of enzymatic processes causing extensive damage of cell structures and 
ultimate cell death [221]. The structural cell injury illustrated in Figure 7 is consistent with these 
proposed mechanisms. Hence the changes observed at the synaptic site, may represent the 
morphological counterpart of altered molecular pathways at the level of the synapse.  
4) Astrocytes, as do neurons, express GluRs providing the binding effectors site for DOM and show 
degenerative structural changes in response to DOM exposure [119,151]. Failure of astrocytes to 
remove extracellular glutamate is one of the key compounding mechanisms implicated in DOM 
neurotoxicity [119]. DOM decreased glutamate uptake in rat astrocytes in vitro, suggesting that 
disruption of astrocytic neuroprotective mechanisms and failure of astrocytes to remove excess 
glutamate at the synaptic site contribute to the excitotoxicity of DOM. In addition, Mayer et al. 
[124], showed that DOM, at in vitro concentrations that are toxic to neuronal cells, can trigger brain 
microglia to release statistically significant amounts of tumor necrosis factor [TNF]-alpha and 
matrix metalloproteinase 9 [MMP-9]. Furthermore, endothelial PGE2 appears to be activated under 
pathological conditions promoting Ca dependent glutamate release from astrocytes, which in turn 
affects the neurons [222]. Astrocytes as neurons have shown regional preferential susceptibility to 
DOM, when assessed using primary astrocyte cell culture [151]. This correlates with the regional 
distribution of DOM brain injury.  
5) Many factors have been reported to potentiate or inhibit the excitotoxic effects of DOM. 
Neuronal inhibition is of paramount importance in maintaining the delicate and dynamic balance 
between excitatory and inhibitory influences in the CNS. GABA [gamma-aminobutyric acid], the 
primary inhibitory neurotransmitter in brain, exerts its fast inhibitory effects through GABA 
receptors [223], hence it is neuroprotective. On the other hand inhibition of GABA has been 
implicated in DOM induced neurotoxicity [224]. Benzodiazepines appear to selectively suppress 
the neuronal activation induced by KA, suggesting that a rapid treatment with high doses of 
benzodiazepines could possibly prevent irreversible hippocampal damage [182]. During the human 
intoxication of 1987, some patients had seizures that were relatively resistant to Dilantin
R 
medication, requiring high doses of intravenous benzodiazepine and phenobarbital for control 
[87,90].  
 
The pineal hormone melatonin appears to be neuroprotective and attenuates the excitotoxic effect of 
DOM and KA [225,226]. The pineal gland produces melatonin under the control of the central clock, 
the suprachiasmatic nucleus [SCN] [227,228]. Melatonin plays an important role in the regulation of 
circadian rhythms, and also acts as antioxidant and neuroprotector which may be of importance in 
aging [227,228]. A decreased production of melatonin with age is well documented; hence it is 
feasible that this functional decline plays a role in the increased susceptibility to DOM toxicity 
associated with old age.  Mar. Drugs 2008, 6                 
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Other factors that may also influence the excitotoxicity effects of DOM includes the basic fibroblast 
growth factor (bFGF), the neurotrophin NT3 and the H1 receptor antagonist terfenadine [229-232]. 
Basic fibroblast growth factor (bFGF) showed in vitro neuroprotective effect from excitatory amino 
acids, while increasing the formation of cGMP evoked by DOM via AMPA/KA receptors [232]. This 
neuroprotection following bFGF treatment may be associated to the modulation of neurochemical 
pathways dependent upon extracellular calcium influx. On the other hand a significantly increases 
DOM toxicity was associated with the neurotrophin NT3 and the H1 receptor antagonist terfenadine in 
vitro exposure [230, 232].  
Figure 8. Illustration of the key proposed mechanisms of tissue cell injury induced by 
DOM with photographs of target sites. The diagram shows the interaction between the 
presynaptic and the postsynaptic terminal. Glutamate receptors in target tissues such as the 
hippocampus are activated by EEAs such as DOM, which at the same time induces the 
release of glutamate. The figure shows vesicular release of glutamate into the synaptic 
space, activation of the post synaptic receptor systems, re-uptake into the pre synaptic 
terminal, and surrounding glia cells (astrocytes). DOM and glutamate activate the various 
glutamate receptors present in the postsynaptic membrane, inducing cellular injury through 
a common injury pathway, a process known as excitotoxicity. This process can be 
separated into several overlapping components:1)The iGluRs are ion-gated channels 
selective to Na
+, K
+ and Ca
+2 and any sustained stimulation of these receptors may results 
in osmotic tissue damage. Hence, neuronal cell swelling reflects the influx of extra cellular 
Na
+, Cl
- and water. Focal swellings along the dendrites
  called varicosities are early 
structural changes and are viewed as a hallmark of excitotoxic neuronal injury. 2) 
Activation of iGluRs triggers the influx of Ca
+2 from the extra cellular environment to the 
synaptic cleft. This stage is marked by delayed cell degeneration. The accumulation of 
Ca
+2 is the crucial determinant of injury. This elevation of Ca
+2 triggers the activation of 
several enzymes: calmodulin (CAM), protein kinase (PKC), nitric oxide synthase (NO 
synthase), phospholipase A2 (PLA2) and reactive oxygen species (ROS). Evidence 
indicates that the mitochondrion plays a central role in the processes of excitotoxic 
neuronal cell degeneration with a web of interactions between Ca
+2 homeostasis, ATP 
production, and the generation and detoxification of ROS. 3) GluRs are found localized at 
the synapse within electron dense structures known as postsynaptic density (PSD), 
mediating the binding of GluRs to sub membrane proteins such as actin and PDZ 
containing proteins. These proteins mediate protein-protein interactions. GluRs PDZ-
containing proteins bind to numerous signal molecules including nitric oxide synthase, 
providing a mechanism for clustering GluRs with the corresponding signalling 
transduction protein. These GluRs associated proteins and excitotoxic signalling result in a 
free radical cascade and activation of enzymatic processes causing extensive damage of 
cell structures and ultimate cell death. 4) Astrocytes, as do neurons, express GluRs 
providing the binding effectors site for DOM and show degenerative structural changes in 
response to DOM exposure. Failure of astrocytes to remove extra cellular glutamate is one 
of the key compounding mechanisms implicated in DOM neurotoxicity. (Diagram - 
modified from Gill and Pulido [131])  Mar. Drugs 2008, 6                 
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Figure 8. Cont. 
 
 
 
7. Discussion and conclusions 
Seafood is a major internationally traded commodity that can be associated with food-borne 
illnesses, including intoxications, allergies and infections [233]. Marine biotoxins are of interest to the 
seafood industry, government regulators and health care practitioners as these naturally produced Mar. Drugs 2008, 6                 
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toxins can enter the food chain and induce illnesses. DOM is among the marine biotoxins of interest to 
public health world wide. The following are some conclusion highlights. 
The human poisoning episode of 1987 provided the basis for the establishment of the maximum 
residual limit [MRL] of 20μg DOM/g [20mg/kg] shellfish meat [flesh] on the basis of 250 gr/ shellfish 
meat for a person weight of 60 kg placed in effect in Canada. Subsequent toxicological studies in 
experimental animals support this safety limit. At present this level is also used by other countries and 
is considered as the standard international regulatory level [23].  
The Joint FAO/WHO/IOC ad hoc Expert Consultation on Biotoxins in Molluscan Bivalves 
performed risk assessments for a number of biotoxins present in bivalve mollusks including DOM 
toxin groups [23,49]. The experts agreed that the derived provisional acute reference dose [RfDs] for 
DOM toxin, based on an adult body weight of 60kg was 100 μg/kg BW [23,49]. They also agreed that 
for chronic effects, the available toxicity data was not sufficient to support the derivation of a chronic 
tolerable daily intake [TDI]. From this risk assessment it was also concluded that pregnant women, 
infants and children, people with pre-morbid pathology and elderly adults [> 65 years of age] may be 
more susceptible to the effect of DOM [23,49].  
Pre-morbid pathology, including renal clearance capacity, cardio-vascular status and gastro-
intestinal absorption were among the factors associated with increased severity of the illness in 
humans intoxicated with DOM [4,7,57,85-87]. DOM appears to be rapidly cleared from the systemic 
circulation by renal excretion [57]. Further, DOM poorly penetrates the intact BBB in rodents [51]. 
This indicates that conditions of impaired renal function or compromised BBB integrity confer 
additional risk. 
Data from cases of human intoxication indicate that the elderly are more susceptible to DOM 
toxicity [4,7,57,85-87]. There is considerable experimental evidence of persisting behavioral and 
morphological effects after early postnatal exposure to doses of DOM below those considered toxic in 
adult animals [37,38,40-42,61,155]. These data support the view of a higher susceptibility of the 
developing brain. However, in these studies DOM was delivered through parenteral routes. DOM 
toxicity is mitigated by its poor absorption through the GI tract. In the Truelove et al. [81] study the 
low dose [0.1 mg/kg] was approximately equivalent to the dose that would result from a 50 kg person 
consuming a 250-g portion of mussel meat containing the present limit of 20mg/kg [20μg /g] DOM. 
The high dose [5 mg/kg] was equivalent to the estimated maximum dose received during the Canadian 
ASP incident of 1987 and was approximately 1/7th that required to cause overt clinical signs in the rat 
[6]. In this study all parameters tested remained unaltered, except for some ultrastructural changes in 
the CA3 region of the hippocampus in the high dose group [81-83]. The concentration of DOM in 
serum and in 24 urine samples from the low dose [0.1 mg/kg] group were below the detection limits of 
the method [150ng/ml]. The daily amount excreted in the urine was considered an estimate of the 
amount absorbed, as there was no evidence of significant metabolic changes or accumulation [81]. The 
lack of absorption from the GI tract was considered as a significant factor in preventing toxicity. 
A recent study provides evidence that DOM is transferable in the milk of lactating rats [45]. The 
authors show transfer of DOM from spiked milk [0.3 and 1.0 mg/kg] to the plasma of nursing neonatal 
rats with an overall longer DOM retention in milk than in plasma after 8 hr exposure of the dams. 
DOM acid was detectable in milk up to 24 hr after exposure [1.0 mg/kg] of the mothers, although the 
amount of DOM transferred in milk after exposure was not sufficient to cause acute symptoms in Mar. Drugs 2008, 6                 
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neonates. This study indicates that an experimental acute DOM exposure event in neonatal rats at the 
doses tested was insufficient to cause any acute observable effects in neonates. It was calculated that 
the amount of DOM a neonate may be exposed to following a single feeding [60 ng/kg] from a dam 
receiving 1.0 mg/kg is about 1/4000th of an oral dose causing observable symptoms in neonates. This 
study is consistent with the view that DOM is poorly absorbed by the GI tract. Although the study 
shows no effect at the calculated exposure dose of 60 ng/kg, it does not preclude that higher doses may 
have an effect. Furthermore, the fact that DOM is transferred to milk opens the possibility of a risk for 
neonatal exposure by this route. 
There is also evidence suggesting that factors such as nutritional status, physical activity, sleep and 
pineal function may also influence the susceptibility to DOM toxicity.  
 The available data base indicates that the acute excitotoxic, epileptogenic and neurobehavioral effects 
of DOM have been the most studied. There is agreement that DOM induces a dose dependent acute 
neurotoxicity characterized by a constellation of neurobehavioral signs, ranging from disorientation to 
seizure, coma and death. Histopathology hallmarks of acute excitotoxicity have a specific anatomical 
distribution. The hippocampus and other structures within the limbic system appear as preferential 
targets and the lesion involves neurons and glia cells. In the neurons a preferential dendritic effect has 
been described. The long term effect in humans and animals surviving the acute episode includes 
memory and learning impairments. Hippocampal gliosis is the histopathology counterpart for the long 
term sequel.  
A 3-D mapping of the mouse brain injury and data using magnetic resonance imaging, 
electroencephalography and markers of neural injury support the findings of preferential regional 
distribution of DOM toxicity as identified by histopathology in other studies [93,112].  
A great body of knowledge has been acquired on the mechanisms involved in DOM excitatory 
neurotoxicity and neuroprotection [Section 5]. Several mechanisms have been implicated as mediators 
for the effects of DOM. Of particular importance is the role played by GluRs as mediators of 
excitatory neurotransmission, the modulation of GABA inhibitory neurotransmission, the concomitant 
excess release of glutamate at the synaptic site, the activation or deactivation of protective mechanisms 
and the involvement of cells and structures such as astrocytes, the BBB and the circumventricular 
organs. These data reveal a complex interplay of cellular, molecular and electrophysiological 
mechanisms that are at least in part dependent on the anatomical region, dose, age, gender and specie. 
In addition, the use of DOM as a research tool has resulted in great advances in the understanding of 
conditions such as epilepsy.  
From this review several gaps were identified that will need further investigation and that are 
relevant to health risk assessment of DOM and other excitatory amino acids in food. These include: 1) 
Developmental gestational neurotoxicology effects of chronic/subchronic oral exposure to low doses 
of DOM, using as reference dose those equivalent to the current MRL. 2) Time points and recovery 
times to further assess long term effects. 3) Risk of DOM exposure through milk. 4) Developmental 
neurotoxicology effects of oral exposure to mixtures of EEAs in foods. 5) Based on the current 
knowledge of GluRs in peripheral tissues and on the view of a common pathway for cell and tissue 
injury further investigations are needed on the effect of DOM in other tissues such as heart, the 
immune system, neuroendocrine system and the gastro-intestinal tract. Mar. Drugs 2008, 6                 
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Annexes 
a) Abbreviations 
 
Amnesic  Shellfish  Poisoning         ASP   
 
α-amino-3-hydroxy-5-methyl-4-isoxazole propionic acid     AMPA 
Blood  brain  barrier          BBB   
C a l c i u m            C a
+2  
Central  Nervous  System         CNS   
Cerebellar  granular  neurons       CGNs 
D o m o i c   a c i d          D O M  
Dorsal  root  ganglia  cells       DRG 
Excitatory  amino  acids         EAAs   
Food and Agriculture Organization of the United Nations    FAO 
Gamma-aminobutyric  acid         GABA   
Gastro  intestinal          GI 
Glial  fibrillary  acidic  protein       GFAP 
Glutamate           Glu 
Glutamate  receptors          GluRs   
Immunohistochemistry         IH 
Insulin-like  growth  factor  I         IGF-I 
Intergovernmental Oceanographic Commission of UNESCO  IOC 
Ionotropic  glutamate  receptors      iGluRs 
Kainic  acid/kainate        KA 
Lactate  dehydrogenase           LDH 
M a g n e s i u m            M g
+2 Mar. Drugs 2008, 6                 
 
 
204
Magnetic resonance imaging microscopy         MRM 
Matrix  metalloproteinase  9       MMP-9 
Maximum  residual  limit       MRL 
Metabotropic  glutamate  receptors      mGluRs 
N-methyl-D-aspartate          NMDA   
Post  natal  day           PND 
Post-synaptic  density          PSD 
P o t a s s i u m            K
+  
S o d i u m            N a
+ 
Suprachiasmatic  nucleus       SCN 
Tolerable  daily  intake        TDI. 
Tumor  necrosis  factor-alpha       TNF-α 
Thyroid  stimulating  hormone       TSH 
World  Health  Organization       WHO 
 
Technical Notes: 
1. Anatomical reference for the hippocampus 
The term hippocampal formation comprises the dentate gyrus; the hippocampus (or hippocampus 
proper); subiculum; presubiculum and entorhinal cortex. For the hippocampus proper the principal 
cellular layer is formed by a row of densely packed pyramidal cells (Py) also known as the Ammon’s 
horn. The layer of pyramidal cells appears as a curved line, the cornus ammonis (CA), which is 
divided into subfields: CA1, CA2, and CA3. The terminal portion of the CA3 inserts within the V 
formed by the limbs of the dentate gyrus (DG). CA2 is a small area between CA3 and CA1.The 
dentate gyrus (DG) is a cytoarchitectonic region within the hippocampal formation and includes the 
granule cell layer (GL), the molecular layer (ML) and the CA4, also known as polymorphic cell layer 
(PoDG) or hilus. The granular cell layer is primarily densely packed columnar stacks of granular cells 
that with the molecular layer forms a V or U- shaped structure that encloses the CA4. [107]. 
2. Anatomical reference for the retina 
The cellular organization of all vertebrate retinas follows the same basic plan: two synaptic layers 
(outer and inner plexifom layers) are intercalated between three cellular layers (outer and inner nuclear 
layers and ganglion cell layer). Light, entering the eye, passes through the retina and is captured by the 
photoreceptor cells. The cell body (perikarya) of the photoreceptors are located in the outer nuclear 
layer, whereas the cell bodies for the other retinal neurons (horizontal cells, bipolar cells, amacrine and 
interplexiform cells) are in the inner nuclear layer. The perikarya of the ganglion cells make up the 
ganglion cell layer [234]. Mar. Drugs 2008, 6                 
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3. Immunohistochemistry (IH) method [235]  
a. Microwave antigen recovery method  
Paraffin embedded sections (5-6 µ thickness) are mounted on charged slides (Surgipath, Winnipeg). 
Sections are deparaffinized and passed through a series of 100% ethanol. Endogenous peroxidase sites 
in the tissue are blocked in a 0.5% hydrogen peroxide/100% ethanol solution, then rinsed in 95% 
ethanol and double distilled water. The slides are transferred into coplin jars of 10 mM sodium citrate 
buffer (BDH), pH 6.0 and then microwaved for two 3 minute periods at 450W with gentle agitation. 
After cooling to room temperature, the slides are processed for immunohistochemistry as follows: 
b. Streptavidin-biotin complex indirect method  
The procedure begins with the deparaffinization, blocking of peroxidase sites and microwave 
antigen retrieval as described above. Then the slides are blocked for avidin and biotin sites to ensure 
specific staining. Slides are processed for IH using the Streptavidin-Biotin Complex Indirect Method 
(LAB/Dakopatts, Dimension Lab., Mississuaga, ON) as follows: slides are incubated with the primary 
antibody (Ab) at a previously determined concentration overnight at 4°C in 15% normal serum 
specific to the type of antibody. A biotinylated F (ab') 2, secondary antibody (2° Ab) directed against 
the primary Ab is diluted (1:100) in 15% antibody specific normal serum. . The slides are incubated 
for 1 hour at room temperature, followed by 30 minutes incubation at room temperature with 
streptavidin against the biotinylation on the 2° Ab at (1:200) dilution. The chromogen most often used 
is 3, 3’-diaminobenzidine tetrahydrochloride (DAB, 40 mg/36 ul of 30% H2O2 in 200 ml of Tris 
buffer). Tissues are counter-stained with instant hematoxylin.  
 
For the illustration in Fig. 5, the glial fibrillary acid protein (GFAP) antibody was obtained from 
(Chemicon International Inc., Temecula, CA, USA) and used at 1:500 dilution.  
4. Electron microscopy method 
For electron microscopy, animals were exsanguinated under deep isofluorine anesthesia and then 
perfused through the heart with heparinized Tyrode=s solution followed by a fixative containing 2% 
glutaraldehyde: 2% paraformaldehyde in Tyrode=s solution. Following perfusion the brain was 
removed and placed in fresh fixative, containing 2% glutaraldehyde: 2% paraformaldehyde in 0.1 M 
sodium cacodylate buffer at pH 7.2, where they remained for at least 3 hours at 4 degrees. Selected 
samples from the CA3 region of the hippocampus were dehydrated through a graded series of alcohols, 
cleared with propylene oxide, then infiltrated and embedded in epoxy resin. Semi-thin sections were 
viewed and areas selected for thin sections. Thin sections (pale gold to silver refractive colour) were 
cut and mounted on 200 mesh grids, stained with uranyl acetate and lead citrate and then viewed on a 
Zeiss 902 transmission electron microscope. 
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